Li Zheng-Mei, Fan Zhen-Lin, Wang Xiao-Yin, Wang Tian-Yun
School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.
International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang, China.
Front Bioeng Biotechnol. 2022 Jul 4;10:880155. doi: 10.3389/fbioe.2022.880155. eCollection 2022.
Recombinant therapeutic proteins (RTPs) are important parts of biopharmaceuticals. Chinese hamster ovary cells (CHO) have become the main cell hosts for the production of most RTPs approved for marketing because of their high-density suspension growth characteristics, and similar human post-translational modification patterns et al. In recent years, many studies have been performed on CHO cell expression systems, and the yields and quality of recombinant protein expression have been greatly improved. However, the expression levels of some proteins are still low or even difficult-to express in CHO cells. It is urgent further to increase the yields and to express successfully the "difficult-to express" protein in CHO cells. The process of recombinant protein expression of is a complex, involving multiple steps such as transcription, translation, folding processing and secretion. In addition, the inherent characteristics of molecular will also affect the production of protein. Here, we reviewed the factors affecting the expression of recombinant protein and improvement strategies in CHO cells.
重组治疗性蛋白(RTPs)是生物制药的重要组成部分。中国仓鼠卵巢细胞(CHO)因其高密度悬浮生长特性、与人相似的翻译后修饰模式等,已成为生产大多数获批上市的RTPs的主要细胞宿主。近年来,针对CHO细胞表达系统开展了许多研究,重组蛋白表达的产量和质量得到了大幅提高。然而,一些蛋白在CHO细胞中的表达水平仍然很低,甚至难以表达。迫切需要进一步提高产量,并在CHO细胞中成功表达“难表达”蛋白。重组蛋白的表达过程是复杂的,涉及转录、翻译、折叠加工和分泌等多个步骤。此外,分子的固有特性也会影响蛋白的产生。在此,我们综述了影响CHO细胞中重组蛋白表达的因素及改进策略。